Electron spin labeled ice binding compounds used for carrying paramagnetic centers for dynamic nuclear polarization
10562937 ยท 2020-02-18
Assignee
Inventors
Cpc classification
C07K14/00
CHEMISTRY; METALLURGY
International classification
C07K14/00
CHEMISTRY; METALLURGY
Abstract
Spin-labeled ice binding compounds (IBCs) including ice binding proteins (IBPs) or antifreeze proteins (AFPs) and their analogs may carry paramagnetic centers for dynamic nuclear polarization (DNP), for enhancing nuclear magnetic resonance (NMR) signal intensities. Use of spin-labeled IBCs to perform DNP exploits the IBCs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high DNP efficiency. Other advantages of using spin-labeled IBCs include cryo-protecting biological samples; cryo-preserving relative positions and orientations of the spin labeling groups; selecting positions and orientations of spin labeling groups with freedom and without technical barriers to making multiple spin labels in an IBC; and enabling use of a solvent that is primarily water for DNP at low temperatures in view of the potentially high water solubilities of spin-labeled IBCs.
Claims
1. A modified ice binding compound, comprising an ice binding compound having a functional group, and an electron spin label covalently bound to the ice binding compound through the functional group.
2. The modified ice binding compound of claim 1, wherein the ice binding compound comprises an antifreeze protein or a mutant thereof.
3. The modified ice binding compound of claim 2, wherein the ice binding compound comprises the antifreeze protein.
4. The modified ice binding compound of claim 3, wherein the antifreeze protein is selected from the group consisting of fish antifreeze glycoproteins (AFGP), type I, II, III and IV AFPs, insect AFPs, and plant AFPs.
5. The modified ice binding compound of claim 2, wherein the ice binding compound comprises the mutant of the antifreeze protein.
6. The modified ice binding compound of claim 5, wherein the mutant is a cysteine substitution mutant of the antifreeze protein.
7. The modified ice binding compound of claim 2, wherein the functional group is selected from the group consisting of an N-terminus, a C-terminus, and side chains of cysteine, serine, threonine, tyrosine, lysine, aspartic acid, glutamic acid, histidine, tryptophan and arginine residues.
8. The modified ice binding compound of claim 7, wherein the electron spin label comprises a paramagnetic metal ion, a nitroxyl radical, a trityl radical, and a bisdiphenylene--phenylallyl radical.
9. A kit comprising the modified ice binding compound of claim 1 and instructions for using the modified ice binding compound.
10. The kit of claim 9, further including a member of the group consisting of cyclodextrins, derivatives thereof, and combinations thereof.
11. A method of making a modified ice binding compound, comprising: a) reacting an electron spin label with an ice binding compound having a functional group to covalently bind the electron spin label to the functional group and form the modified ice binding compound; and b) purifying the modified ice binding compound.
12. The method of claim 11, wherein the ice binding compound comprises an antifreeze protein or a mutant thereof.
13. The method of claim 12, wherein the ice binding compound comprises the antifreeze protein.
14. The method of claim 12, wherein the ice binding compound comprises a cysteine substitution mutant of the antifreeze protein.
15. The method of claim 12, wherein the functional group is selected from the group consisting of an N-terminus, a C-terminus, and side chains of cysteine, serine, threonine, tyrosine, lysine, aspartic acid, glutamic acid, histidine, tryptophan and arginine residues, and the electron spin label comprises a paramagnetic metal ion, a nitroxyl radical, a trityl radical, and a bisdiphenylene--phenylallyl radical.
16. A method of studying molecules in a sample, comprising: a) dissolving or otherwise homogeneously mixing the sample for analysis with the modified ice binding compound of claim 1, and b) studying the molecules in the sample by magnetic resonance.
17. The method of claim 16, wherein the sample comprises a biological sample.
18. The method of claim 16, further comprising freezing the dissolved or homogeneously mixed sample for analysis and the modified ice binding compound, and optionally varying a temperature while studying the molecules by magnetic resonance.
19. A method of magnetic resonance imaging, comprising: a) freezing a solution of the modified ice binding compound of claim 1 and a solvent comprising water; b) thawing the solution; c) injecting the thawed solution into a tissue or tissue structure; and d) conducting an MM procedure on the tissue or tissue structure.
20. The method of claim 19, further comprising filtering the modified ice binding compound from the solution prior to injecting the thawed solution into the tissue or tissue structure.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
DETAILED DESCRIPTION
(11) Throughout this specification, the terms a and an and variations thereof represent the phrase at least one. In all cases, the terms comprising, comprises and any variations thereof should not be interpreted as being limitative to the elements listed thereafter. Unless otherwise specified in the description, all words used herein carry their common meaning as understood by a person having ordinary skill in the art. In cases where examples are listed, it is to be understood that combinations of any of the alternative examples are also envisioned. The scope of the invention is not to be limited to the particular embodiments disclosed herein, which serve merely as examples representative of the limitations recited in the issued claims resulting from this application, and the equivalents of those limitations.
(12) Site Directed Spin Labeling (SDSL)
(13) Site Directed Spin Labeling (SDSL) is often accomplished by cysteine-substitution mutagenesis, followed by modification of the unique sulfhydryl group with selective nitroxide or other reagents.
(14) Presently, five types of fish AFPs have been discovered, including antifreeze glycoprotein (AFGP) and type I, II, III and IV AFPs. AFPs also have been found in insects such as Tenebrio molitor, spruce budworm, and snow flea, and in plants such as winter rye (Secale cereale L.) and ryegrass (Lolium perenne). Although AFPs have different structures and were found in diversified species, they all display similar antifreeze function by binding to specific surfaces, and preventing the growth of seed ice crystals at subzero environment. Thus, other compounds with similar functional capabilities are contemplated as similarly useful for the methods disclosed herein and they are also included within the scope of IBCs. A summary of typical structures of several AFPs are given in
(15) Single Spin-Labeled AFPs
(16) As an example, the HPLC6 isoform of type I AFP has an -helical secondary structure (see
(17) Spin labels may be attached to Cys side chains according to standard procedures (
(18) The Overhauser Effect (OE) was originally proposed to enhance nuclear spin's polarization from that of electron spins. OE involves the simultaneous transitions of an electron spin and a nuclear spin driven by relaxation processes induced by time-dependent dipolar and/or scalar electron-nuclear couplings. However, the efficiency of the OE is lowered dramatically at higher magnetic fields because .sub.0.sub.c<1 must be satisfied, where .sub.0 is the electron Larmor frequency and .sub.c is the rotational correlation time of the molecules. Thus, it is necessary to find other DNP mechanisms to enhance the nuclear spin's polarization at high magnetic fields for enhancing the signals of modern NMR and MRI.
(19) One of the DNP mechanisms is the Solid Effect (SE), which is a two-spin process. Single spin-labeled IBPs facilitate this mechanism. Microwave irradiation at .sub.0S.sub.01, where .sub.0S and .sub.01 respectively denote the electronic and nuclear Larmor frequencies, can excite the partially allowed electron-nucleus transitions. For the SE to be effective, the inhomogeneous breadth () and the homogeneous linewidth () of the Electron Paramagnetic Resonance (EPR) spectrum should be much smaller than the nuclear Larmor frequency (.sub.01>, ) so that only one of the two forbidden transitions can be excited at a time to avoid cancellation. Additionally, the transition probability has a frequency dependence as 1/(.sub.01).sup.2. Thus, the SE's efficiency will decrease quickly with the increase of the magnetic field, resulting in poorer efficiency at high field. Two readily available radicals that have sufficiently narrow linewidths are bisdiphenylene--phenyl allyl (BDPA) and trityl (
(20) Double Spin-labeled AFPs
(21) SDSL can also be used to make double spin-labeled AFPs. In the following HPLC6 sequence: Asp-Thr-Ala-Ser-Asp-Ala-Ala-Ala-Ala-Ala-Ala-Leu-Thr-Ala-Ala-Asn-Ala-Lys-Ala(19)-Ala(20)-Ala-Glu-Leu(23)-Thr-Ala-Ala-Asn-Ala-Ala-Ala-Ala-Ala-Ala-Ala-Thr-Ala-Arg [SEQ ID NO:1], the preferred residues selected for double Cys substitutions are bolded and numbered. These residues are not in the IBS and are located around the mid-section of the a-helix. For example, the following double Cys-substitution mutants can be designed: (1) HPLC6_A19C_L23C; (2) HPLC6_A20C_L23C; and (3) HPLC6_A19C_A20C.
(22) To make double spin-labeled IBPs, spin labels are attached to the Cys side chains according to the standard procedures (
(23) Another DNP mechanism is the Cross Effect (CE). The double spin-labeled IBPs facilitate the CE, which involves two electrons that are in close physical proximity in order to be effectively dipolarly coupled. To have the CE, the difference of the two EPR frequencies should match the nuclear frequency (.sub.0S1.sub.0S2=.sub.01). The CE is the dominant mechanism in the regime >.sub.01>. When two transitions matching the condition above, one from an inhomogeneous line broadening packet .sub.1 and the other from the other .sub.2, the frequency difference of the two transitions goes into polarizing the nuclear spins. This mechanism is a three-spin process and is based on allowed EPR transitions which exhibit a 1/(.sub.01) field dependence. Therefore, the CE is more efficient than the SE. Examples of biradicals that support CE are shown in
(24) Multiple Spin-labeled AFPs
(25) SDSL can also be used to make triple and multiple spin-labeled AFPs. In the following HPLC6 sequence: Asp-Thr-Ala-Ser-Asp-Ala-Ala-Ala-Ala-Ala-Ala-Leu(12)-Thr-Ala-Ala-Asn-Ala-Lys-Ala(19)-Ala(20)-Ala-Glu-Leu(23)-Thr-Ala-Ala-Asn-Ala-Ala-Ala-Ala-Ala-Ala-Ala-Thr-Ala-Arg [SEQ ID NO:1], the preferred residues selected for Cys substitutions are bolded and numbered. These residues are not in the IBS and located around the mid-section of the -helix. For example, the following Cys-substitution mutants can be designed:
(26) Triple Cys-substitution mutants: (1) HPLC6_L12C_A19C_L23C; (2) HPLC6_L12C_A20C_L 23C; (3) HPLC6_L19C_A20C_L23C; and (4) Quadruple Cys-substitution mutant: HPLC6_L 12C_A19C_A20C_L23C.
(27) In addition to the distances between the pairs of -carbons in the double Cys substituted mutants, the distance between the C12 C.sub. and C23 C.sub. is 16.6 , that between the C12 C.sub. and C20 C.sub. is 12.8 , and that between the C12 C.sub. and C19 C.sub. is 10.5 . To make the multiple spin-labeled IBPs, the spin labels are attached to the Cys side chains according to the standard procedures (
(28) Another DNP mechanism is Thermal Mixing (TM). Multiple spin-labeled AFPs facilitate the TM effect, which involves multiple electron spins and the EPR spectrum is homogeneously broadened. The conditions under which the TM is the dominant mechanism are >.sub.01, .
(29) Using the Native Functional Side Chains of Proteins to Make Spin-labeled IBPs
(30) The native functional side chains in IBPs may also be used for spin-labeling. This method does not require Cys-substitution mutagenesis. However, the choices for selecting the spin-labeled sites may be more limited by the available functional side chains. Examples of functional groups in the side chains in peptides or proteins that can be used to perform spin labeling are listed in
(31) Other Spin-labeled Compounds Having the Ability to Bind to Ice Surfaces for DNP
(32) Other compounds that are not peptides or proteins but that may be the complexes of peptides or proteins, and organic and/or inorganic molecules, any of which possess ice binding properties and have functional side chains as described in the sections Site Directed Spin Labeling (SDSL) and
(33) Using Free Radicals for Synthesizing Paramagnetic Centers for DNP
(34) Compounds containing stable free radicals (which contain unpaired electron spins) that can be used to perform spin labeling of IBPs include, but are not limited to those given in
(35) Labeling Paramagnetic Ions to IBPs for DNP
(36) Paramagnetic metal ions including those of transition, actinide, and lanthanide metals contain unpaired electron spins which can also be used to polarize nuclear spins through DNP. These ions may be attached to IBPs through chelating ligands. Chelating ligands are known to use more than one atom to bind to a metal ion to form an ion complex with high stability. For example, chelating agents like DTPA (pentetic acid, or diethylene triamine pentaacetic acid) and EDTA (ethylenediamine tetraacetic acid) or their derivatives, can easily complex Gd.sup.3+. These ligands with chemical bonding to extra functional groups such as those described in
(37) The paramagnetic metal ions that can be used for DNP include, for example, lanthanide metals of atomic numbers 58-70, transition metals of atomic numbers 21-29, 42 and 44. Suitable paramagnetic ions include, for example, Cr.sup.3+, Mn.sup.2+, Fe.sup.3+, Fe.sup.2+, Co.sup.2+, Ni.sup.2+, Cu.sup.2+, Nd.sup.3+, Sm.sup.3+, Gd.sup.3+, Tb.sup.3+, Dy.sup.3+, Ho.sup.3+, Er.sup.3+ and Yb.sup.3+.
(38) A variety of chelating agents is known to form ion complexes. Generally, chelating agents often containing heteroatoms as electron pair donors, such as N and/or O, and may also contain P and/or S. DTPA, for example, is an often-used acyclic chelating agent. Its functional derivatives include DTPA-BMA, DTPA-BP, DTPA-BMEA, EOB-DTPA, BOPTA and MS-325. EDTA is another commonly used acyclic chelating agent. Its functional derivatives include EDTA-BMA, DPDP, PLED, HPTA, amides or diamides, such as TOGDA, sulphonates and phosphonates. Cyclic chelating agents may also be used for this purpose, and include, for example, cryptands, PCTA-[12], PCTP-[12], PCTP-[13], DOTA, DO3A and derivatives thereof, such as HP-DO3A and DO3A-butriol.
(39) Paramagnetic metal ions of one or different metals may be used to make paramagnetic ionic spin-labeled IBPs and ice binding compounds (IBCs). The combinations of the organic radicals as discussed herein can also be attached to the same IBPs. The combination of the free radical spin-labeled IBPs and the paramagnetic ion labeled IBPs can also be used in a single solution for DNP.
(40) Storage and shipment of the spin-labeled IBCs prepared according to the general methods disclosed herein would be readily apparent to any person having ordinary skill within the art. For example, the spin-labeled IBCs could be freeze dried and stored in airtight containers, preferably at 20 C. for prolonged shelf life.
(41) DNP NMR may be performed according to standard procedures that would be readily apparent to any person having skill within the art. For example, a sample for analysis may be dissolved in, or otherwise homogeneously mixed with a spin-labeled IBC solution. After being frozen at low temperature, the DNP process for the sample may be performed followed by optional temperature variation and NMR procedure.
(42) Likewise, imaging tissue structures, including cells, may also be performed according to standard procedures. For example, 41 of water of a spin-labeled IBC solution may be polarized through DNP at low temperature. Thereafter, the frozen solution may be promptly thawed to liquid state. Finally, the polarized solution may be injected into the tissue sample for analysis followed by an MM procedure. The spin-labeled IBC can also be filtered out leaving only water to be injected into the tissue.
(43) For tissues, including cells, where low temperature may not cause serious damage to the structures, or where the structures at low temperature will be studied, tissues soaked with spin-labeled IBC, for example, through injection or diffusion, can be frozen directly at low temperature for DNP, which can be followed by optional temperature variation and then by an MRI procedure.
EXAMPLE 1
EPR Experimental Results of Single and Double Spin-labeled HPLC6 Peptides Using the IAP Reagent
(44) We have synthesized the single spin-labeled HPLC6_L12 and double spin-labeled HPLC6_A20C_L23C using the IAP reagent. The EPR spectra of their water solutions at different temperatures are shown in
EXAMPLE 2
Using the Native Functional Groups of HPLC6 Isoform of Type I AFP
(45) This AFP has the following sequence: Asp-Thr-Ala-Ser-Asp-Ala-Ala-Ala-Ala-Ala-Ala-Leu-Thr-Ala-Ala-Asn-Ala-Lys-Ala-Ala-Ala-Glu-Leu-Thr-Ala-Ala-Asn-Ala-Ala-Ala-Ala-Ala-Ala-Ala-Thr-Ala-Arg [SEQ ID NO:1], where the ice binding residues are underlined and the residues preferred for performing spin labeling are bolded. The bolded residues include lysine, arginine, glutamic acid and aspartic acid residues. Using these residues, single spin-labeled through spin labeling Lys or Arg side chain, double spin-labeled through spin labeling Lys and Arg side chain, and triple spin-labeled through spin labeling Asp, Asp and Glu side chains, etc., type I AFPs can be synthesized.
EXAMPLE 3
Using the Native Functional Groups of the QAEop12 Isoform of Type III AFP
(46) This protein has the following sequence:
(47) TABLE-US-00001 [SEQIDNO:2] MNQASVVANQLIPINTALTLVMMRSEVVTPVGIPA EDIPRLVSMQVNRAVPLGTTLMPDMVKGYAA
where the residues involved in the putative ice binding surfaces are underlined and the available non-ice binding residues for performing spin labeling are bolded. They include lysine (K), arginine (R), glutamic acid (E), aspartic acid (D) and tyrosine (Y) residues. Using these side chains, single spin-labeled (using K or Y), double spin-labeled (using K and Y) and multiple spin-labeled (using R, R, R for making triple spin-labeled, using E, E, D, D for making quadruple spin-labeled, etc.) type III AFPs can be synthesized.
EXAMPLE 4
Functionalized DTPA Gd3+ Complex for Conjugation to IBPs
(48) As an example, we can synthesize 3-(2-iodoacetamido)-DTPA as shown in